<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975297</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0802</org_study_id>
    <secondary_id>CCTS Research Scholar Award</secondary_id>
    <nct_id>NCT02975297</nct_id>
  </id_info>
  <brief_title>Exenatide Once Weekly for Smoking Cessation</brief_title>
  <official_title>Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a potential new treatment for smoking cessation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal symptoms as assessed by the Wisconsin Smoking Withdrawal Scale</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal symptoms as assessed by the Wisconsin Smoking Withdrawal Scale</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal symptoms as assessed by the Wisconsin Smoking Withdrawal Scale</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal symptoms as assessed by the Wisconsin Smoking Withdrawal Scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cue-induced craving for cigarettes following virtual reality exposure as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cue-induced craving for cigarettes following virtual reality exposure as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence as assessed by self-report</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence as assessed by expired carbon monoxide (CO) levels</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-quit craving as assessed by the Questionnaire of Smoking Urges</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Exenatide plus NRT plus counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plus NRT plus counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once weekly placebo, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.</description>
    <arm_group_label>Exenatide plus NRT plus counseling</arm_group_label>
    <other_name>Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRT</intervention_name>
    <description>Nicotine Patch (21mg) / 24 hours.</description>
    <arm_group_label>Exenatide plus NRT plus counseling</arm_group_label>
    <arm_group_label>plus NRT plus counseling</arm_group_label>
    <other_name>Nicotine patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Brief individual behavioral smoking cessation counseling.</description>
    <arm_group_label>Exenatide plus NRT plus counseling</arm_group_label>
    <arm_group_label>plus NRT plus counseling</arm_group_label>
    <other_name>Smoking cessation counseling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline.</description>
    <arm_group_label>plus NRT plus counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be English-speaking volunteers who desire to quit smoking and are willing to make a
             quit attempt during the course of the study;

          -  Have smoked ≥10 cigarettes a day for at least one year and provide a breath CO ≥10
             ppm;

          -  Have a negative pregnancy test, if female of childbearing potential;

          -  Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters

          -  Not currently using any therapy for glycemic control (either injectable [i.e. insulin]
             or oral agents);

          -  Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90-150
             mmHg systolic and 45-95 mmHg diastolic;

          -  Have hematology and chemistry laboratory tests that are within reference limits
             (within 10% above or below), with the following exception: pancreatic tests (lipase
             and amylase) must be within normal limits;

          -  Have a medical history and brief physical examination demonstrating no clinically
             significant contraindications for study participation, in the judgment of the
             principal investigator.

        Exclusion Criteria:

          -  Meet criteria for the following psychiatric and/or substance use disorders as assessed
             by the MINI: items C (current manic or hypomanic episode only), I (alcohol abuse -
             Alcohol Addendum-past 3 months only; current alcohol dependence), J (substance abuse
             -Substance Abuse Addendum - past 3 months only; current substance dependence), K
             (current psychotic disorder or current mood disorder with psychotic features).

          -  Individuals who meet criteria for non-exclusionary psychiatric disorders that are
             considered clinically unstable and/or unsuitable to participate as determined by the
             Principal Investigator and/or Study Physician.

          -  Individuals rated as moderate (9-16) to high (17 or greater) on suicidality as
             assessed by Module B of the MINI.

          -  Have personal or family history of medullary thyroid carcinoma or multiple endocrine
             neoplasia syndrome type 2;

          -  Have type 1 diabetes mellitus;

          -  Have severe cardiovascular disease (history of myocardial infarction, life-threatening
             arrhythmia, or worsening angina pectoris);

          -  Have active temporomandibular joint disease;

          -  Have severe gastrointestinal disease (i.e. severe gastroparesis);

          -  Have previous history of pancreatitis or are at risk for pancreatitis;

          -  Have CrCl&lt;30;

          -  Have any previous medically adverse reaction to study medications, nicotine, or
             menthol;

          -  Be pregnant or lactating or unwilling to provide a negative pregnancy test before
             study entry;

          -  Not using a reliable form of contraception (e.g., abstinence, birth control pills,
             intrauterine device, condoms, or spermicide);

          -  Have any illness which in the opinion of the primary investigator would preclude safe
             and/or successful completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luba Yammine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luba Yammine, PhD</last_name>
    <phone>832-776-3151</phone>
    <email>luba.yammine@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luba Yammine, PhD</last_name>
      <phone>832-776-3151</phone>
      <email>luba.yammine@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Luba Yammine</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>pre-diabetes</keyword>
  <keyword>overweight</keyword>
  <keyword>exenatide</keyword>
  <keyword>GLP-1 agonists</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

